Candel Therapeutics, Inc.
CADL
$5.71
-$0.24-4.03%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -5.41% | -18.44% | -21.70% | -2.68% | 1.50% |
| Gross Profit | 5.41% | 18.44% | 21.70% | 2.54% | -1.80% |
| SG&A Expenses | 9.66% | 4.91% | -0.06% | -1.12% | -6.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.57% | -9.41% | -14.13% | -2.89% | -2.74% |
| Operating Income | -0.57% | 9.41% | 14.13% | 2.81% | 2.58% |
| Income Before Tax | 55.72% | -5.92% | -45.44% | -63.49% | -55.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 55.72% | -5.92% | -45.44% | -63.49% | -55.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.72% | -5.92% | -45.44% | -63.49% | -55.34% |
| EBIT | -0.57% | 9.41% | 14.13% | 2.81% | 2.58% |
| EBITDA | -0.64% | 9.68% | 14.58% | 3.06% | 2.93% |
| EPS Basic | 60.30% | -2.93% | -33.80% | -57.70% | -52.76% |
| Normalized Basic EPS | 61.22% | -2.37% | -33.56% | -56.48% | -51.56% |
| EPS Diluted | 59.34% | -4.19% | -33.80% | -57.70% | -52.76% |
| Normalized Diluted EPS | 60.54% | -3.27% | -33.56% | -56.48% | -51.56% |
| Average Basic Shares Outstanding | 44.94% | 27.51% | 9.43% | 3.81% | 1.16% |
| Average Diluted Shares Outstanding | 48.60% | 31.20% | 9.43% | 3.81% | 1.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |